Lokesh Narsineni
Senior Scientist, Process Sciences Scribe Therapeutics
Lokesh Narsineni is a Pharmaceutical Scientist with over 10 years of expertise in designing and optimizing lipid/polymer-based nanoparticle systems for gene therapy. His focus areas include RNA-LNP gene-editing (for base editors, Cas9, and CasX/sgRNA delivery), vaccines, and protein replacement therapies.
A recognized expert in the field, Lokesh was trained by pioneers in LNP and mRNA therapeutics and worked on lipid nanoparticles before the COVID era. He gained extensive foundational knowledge from leading laboratories in Canada and the US. He possesses a proven track record in translational drug development, from platform design to IND-enabling studies, with a focus on tissue-specific targeting, including the liver, lung, bone marrow, and skin.
Currently, Lokesh is advancing LNP delivery systems at Scribe Therapeutics for their next-generation CasX and epigenetic editors to enable precision medicine. His research has been recognized with the WB Pearson Medal for his research on innovative LNP-based eye gene therapy nanomedicine solutions. He is an expert in the structural and morphological characterization of RNA-LNPs.
Seminars
- Impact of LNP composition and pKa on the LNP structure, morphology and distribution of the RNA
- Influence of the RNA cargo size on the distribution of RNA, structure and morphology of LNPs and leveraging LNP formulation process to achieve desirable LNP characteristics
- Effect of RNA modifications on the structural and morphology features of an LNPs
NEW DATA
